(151 days)
No
The description focuses on mechanical design and customization based on patient measurements, with no mention of AI or ML algorithms for diagnosis, treatment planning, or device function.
Yes
The device is indicated for mild to moderate obstructive sleep apnea (OSA) and to alleviate or reduce snoring in adults by holding the mandible and base of tongue forward during sleep to improve air exchange and decrease air turbulence, which directly addresses a health condition.
No
Explanation: The device is described as a "mandibular advance device (MAD)" intended to treat obstructive sleep apnea and snoring by repositioning the jaw, not to diagnose these conditions.
No
The device description clearly states it is a physical intraoral mandibular advancement device fabricated using CAD/CAM, consisting of splints and posts. It is a hardware device.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostic devices are used to examine specimens taken from the human body (like blood, urine, tissue) to provide information for diagnosis, monitoring, or screening.
- Device Function: The NOA Sleep Apnea and Snoring Device is an intraoral device that physically repositions the mandible to alleviate snoring and mild to moderate obstructive sleep apnea. It does not analyze any biological samples.
- Intended Use: The intended use clearly states it's a mandibular advance device for treating sleep apnea and snoring, not for diagnostic testing of biological samples.
Therefore, the device's function and intended use fall outside the scope of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
NOA SLEEP APNEA AND SNORING DEVICE is a mandibular advance device (MAD) indicated for mild to moderate obstructive sleep apnea (OSA) and to alleviate or reduce snoring in adults.
Product codes
LRK
Device Description
The NOA Sleep Apnea and Snoring Device is a customized prescription intraoral mandibular advancement device for snoring and obstructive sleep apnea intended for single-patient use by those who are 18 years or older.
The device consists of CAD/CAM fabricated maxillary and mandibular splints connected by symmetrical, twin-mated posts that are customizable to allow lateral jaw movement as well as jaw opening. The series of one or more mandibular splints, and one or more maxillary splints to be exchanged with other splints in the series according to the prescriber, to titrate protrusive jaw movement according to patient comfort and needs. The described mandibular advancement is intended to reduce snoring and mild to moderate obstructive sleep apnea by holding the mandible and base of tongue forward during sleep, to provide increased pharyngeal space to improve the patient's ability to exchange air and decrease air turbulence.
The NOA Sleep Apnea and Snoring Device does not have any additional adjustment mechanisms to modify or maintain the mandibular position such as pistons, straps, repositioning elastics or screws, eliminating the need for utilizing external controlling components such as keys, screwdrivers or ligature ties.
The NOA device is designed with lateral fins called cam and follower. Contact between the cam and the follower prevents any mandibular retrusion even with the opening of the mouth.
The device design is configured according to the patient's specific dental arch, to maximize tongue space and to allow open, close and laterality movements during wear. These movements can be personalized by the doctor. Furthermore, the doctor can change the height of the cam in the prescription to limit the maximum mouth opening during wear.
Orthoapnea NOA device designs can be Standard or Customized.
A Standard device is designed with standard height in the lateral cams among all lower splints. If the practitioner provides a measurement of the antero-posterior mobility (Maximum retrusion), a Customized device is designed decreasing the height of the cam according to the degree of advancement. increases, the ability to open the mouth without mandibular retrusion decreases, making the cam shorter.
The following additional device design features can be customized when ordering the prescription device:
- Advance regulation/titration sequence
- Lateral movement
- Device opening limit
- Frontal opening of the device
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
18 years or older
Intended User / Care Setting
Physician or dentist
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
No clinical testing was performed. Non-clinical testing was used to support the determination of substantial equivalence.
Bench testing included:
- Determination of flexural properties with ISO 178:2010.
- Determinations of the Tensile properties with ASTM D638-02
- Biocompatibility evaluation in accordance with ISO 10993-1 and specifically
- Cytotoxicity testing in accordance with ISO 10993-5:2009;
- Irritation and sensitization testing in accordance with ISO 10993-10:2009.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 872.5570 Intraoral devices for snoring and intraoral devices for snoring and obstructive sleep apnea.
(a)
Identification. Intraoral devices for snoring and intraoral devices for snoring and obstructive sleep apnea are devices that are worn during sleep to reduce the incidence of snoring and to treat obstructive sleep apnea. The devices are designed to increase the patency of the airway and to decrease air turbulence and airway obstruction. The classification includes palatal lifting devices, tongue retaining devices, and mandibular repositioning devices.(b)
Classification. Class II (special controls). The special control for these devices is the FDA guidance document entitled “Class II Special Controls Guidance Document: Intraoral Devices for Snoring and/or Obstructive Sleep Apnea; Guidance for Industry and FDA.”
0
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA acronym along with the full name of the agency on the right. The FDA part of the logo is in blue, with the acronym in a larger font size than the rest of the name. The text reads "U.S. FOOD & DRUG ADMINISTRATION".
February 12, 2021
Orthoapnea S.L. Jose Repolles Llecha Managing Director C / Flauta Magica 22 Malaga, Malaga 29006 SPAIN
Re: K202651
Trade/Device Name: NOA Sleep Apnea and Snoring Device Regulation Number: 21 CFR 872.5570 Regulation Name: Intraoral Devices For Snoring And Intraoral Devices For Snoring And Obstructive Sleep Apnea Regulatory Class: Class II Product Code: LRK Dated: January 15, 2021 Received: January 19, 2021
Dear Jose Repolles Llecha:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal
1
statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Michael E. Adjodha, M.ChE. Assistant Director DHT1B: Division of Dental Devices OHT1: Office of Ophthalmic, Anesthesia, Respiratory, ENT and Dental Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
2
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration
Indications for Use
Form Approved: OMB No. 0910-0120 Expiration Date: 06/30/2023 See PRA Statement below.
510(k) Number (if known) K202651
Device Name
NOA SLEEP APNEA AND SNORING DEVICE
Indications for Use (Describe)
NOA SLEEP APNEA AND SNORING DEVICE is a mandibular advance device (MAD) indicated for mild to moderate obstructive sleep apnea (OSA) and to alleviate or reduce snoring in adults.
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)
| Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
NOA Sleep Apnea and Snoring Device
K202651
510(k) SUMMARY
| DATE OF SUBMISSION: | 2021-02-12 |
|---|---|
| SUBMITTER NAME: | Orthoapnea S.L |
| SUBMITTER ADDRESS: | Calle Flauta Mágica 22 |
| 29006 Málaga | |
| SPAIN | |
| CONTACT: | Jose Repollés Llecha |
| TELEPHONE: | +34 952 122 174 ext. 154 |
| e-mail: | jrepolles@orthoapnea.com |
| DEVICE TRADE NAME: | NOA SLEEP APNEA AND SNORING DEVICE |
| COMMON NAME: | MANDIBULAR ADVANCEMENT DEVICE |
| CLASSIFICATION NAME: | INTRAORAL DEVICES FOR SNORING |
| PRODUCT CODE: | LRK (Anti-snoring device) |
| REGULATION DESCRIPTION: | Device, Anti-snoring (21 CFR 872.5570) |
| PREDICATE DEVICE(S): | K133683 (Microdental) - Primary predicate |
K143244 (Panthera Dental)
A. Description of the Device
The NOA Sleep Apnea and Snoring Device is a customized prescription intraoral mandibular advancement device for snoring and obstructive sleep apnea intended for single-patient use by those who are 18 years or older.
The device consists of CAD/CAM fabricated maxillary and mandibular splints connected by symmetrical, twin-mated posts that are customizable to allow lateral jaw movement as well as jaw opening. The series of one or more mandibular splints, and one or more maxillary splints to be exchanged with other splints in the series according to the prescriber, to titrate protrusive jaw movement according to patient comfort and needs. The described mandibular advancement is intended to reduce snoring and mild to moderate obstructive sleep apnea by holding the mandible and base of tongue forward during sleep, to provide increased pharyngeal space to improve the patient's ability to exchange air and decrease air turbulence.
The NOA Sleep Apnea and Snoring Device does not have any additional adjustment mechanisms to modify or maintain the mandibular position such as pistons, straps, repositioning elastics or screws, eliminating the need for utilizing external controlling components such as keys, screwdrivers or ligature ties.
The NOA device is designed with lateral fins called cam and follower. Contact between the cam and the follower prevents any mandibular retrusion even with the opening of the mouth.
The device design is configured according to the patient's specific dental arch, to maximize tongue space and to allow
4
OrthoApnea
NOA Sleep Apnea and Snoring Device
open, close and laterality movements during wear. These movements can be personalized by the doctor. Furthermore, the doctor can change the height of the cam in the prescription to limit the maximum mouth opening during wear.
Orthoapnea NOA device designs can be Standard or Customized.
A Standard device is designed with standard height in the lateral cams among all lower splints. If the practitioner provides a measurement of the antero-posterior mobility (Maximum retrusion), a Customized device is designed decreasing the height of the cam according to the degree of advancement. increases, the ability to open the mouth without mandibular retrusion decreases, making the cam shorter.
The following additional device design features can be customized when ordering the prescription device:
- Advance regulation/titration sequence
- Lateral movement
- Device opening limit
- Frontal opening of the device
B. Intended Use
NOA Sleep Apnea and Snoring Device is a device that consists of maxillary and mandbular devices connected with a personalized mechanism to reduce snoring and mild to moderate sleep apnea by holding the mandible forward during sleep.
Comparison of Technology ﻥ
Technological characteristics of the NOA Sleep Apnea and Snoring Device are compared to those of the primary predicate – K133683 MicrO2 – and reference device - K143244 Panthera – as listed in Table 1 below.
In all cases, the intended use / indications for use are to reduce or alleviate nighttime snoring and mild to moderate obstructive sleep apnea. In additional, in all cases, the devices are removable, non-sterile and for mandibular adjustment to be performed by the physician or dentist.
The material used for the subject device is different to that of the primary predicate device. However, this same material is used in the reference device.
Also, the mandibular adjustment range for the subject device is wider than that of the primary predicate device but with the range stated for the reference device.
These differences in technology, therefore, do not raise additional concerns of safety and effectiveness.
5
) | ( OrthoApnea
NOA Sleep Apnea and Snoring Device
| Characteristic | Subject Device | Primary predicate | Reference device | Substantially Equivalent
/ Comments |
|--------------------------------|-------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Model Name | NOA Sleep Apnea
and Snoring Device | MicrO2 Obstructive
Sleep Apnea Device | Panthera
Anti-
snoring Device | - |
| 510K number | NA | K133683 | K143244 | - |
| Intended use | Intended to reduce or
alleviate nighttime
snoring and mild to
moderate obstructive
sleep apnea (OSA) in
adults | Intended to reduce
nighttime snoring and
mild to moderate
obstructive sleep
apnea (OSA) in adults | Intended to reduce
or alleviate
snoring and mild
to moderate
obstructive sleep
apnea (OSA) in
adults. | Yes |
| Material | Polymers (Polyamide
12) | Hard PMMA material -
Acrylic (polymethyl
methacrylate) | Polymers
(Polyamide 12) | The material used in the
subject device is NOT same
as the material used in the
primary predicate. However,
the material used in the
subject device is the same
as the material used in the
reference device. |
| Fixed/removable | Removable | Removable | Removable | Yes |
| Sterile | Non- sterile | Non-sterile | Non-sterile | Yes |
| Mandibular
adjustment | Performed
by
physician or dentist | Performed by dentist
or physician | Performed
by
dentist
or
physician | Yes |
| Mandibular
adjustment range | Up to 10.0 mm | Up to 6 mm | Up to 15.0 mm | The mandibular adjustment
range for the subject device
is higher than for the primary
predicate device. However,
the mandibular adjustment
range for the subject device
is within that of the reference
device |
Table 1: Comparison of Technology
D. Non-clinical Performance Testing
The following guidance documents have been taken into consideration:
- Intraoral Devices for Snoring and/or Obstructive Sleep Apnea-Guidance for Industry and FDA -2002
- Technical Considerations for Additive Manufactured Medical Devices-Guidance for Industry and FDA 2017.
The proposed devices have been subject to bench testing to determine fulfillment of design and performance requirements. Bench testing followed the recommendations provided in FDA Guidance Document - Class II Special Controls Guidance Document: Intraoral Devices for Snoring and/or Obstructive Sleep Apnea.
Specific performance testing on the NOA Sleep and Snoring device include:
- Determination of flexural properties with ISO 178:2010.
- Determinations of the Tensile properties with ASTM D638-02 ●
6
) | ( OrthoApnea
NOA Sleep Apnea and Snoring Device
- Biocompatibility evaluation in accordance with ISO 10993-1 and specifically
- . Cytotoxicity testing in accordance with ISO 10993-5:2009;
- Irritation and sensitization testing in accordance with ISO 10993-10:2009.
Test data from the device was leveraged for the previous performance tests based on the use of identical device and packaging materials as well as identical manufacturing, packaging and cleaning processes for the NOA Sleep Apnea and Snoring device.
E. Clinical Performance Testing
No clinical testing was performed. Non-clinical testing was used to support the determination of substantial equivalence.
F. Conclusion
Based on the indications for use and comparison of technology together with the results of non-clinical performance testing, we conclude that our device OrthoApnea NOA Sleep Apnea and Snoring device is substantially equivalent to the predicate device MicrO2 Obstructive Sleep Apnea (K133683).